SG/CALL/BRISTOL-MYERS SQUIBB/60/0.1/21.06.24

SG/CALL/BRISTOL-MYERS SQUIBB/60/0.1/21.06.24 Share Price

DE000SV1KST1

Delayed Deutsche Boerse AG 09:25:59 03/06/2024 pm IST
0.001 ^EUR	0.00%

6 months	-98.57%
Current year	-98.75%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart SG/CALL/BRISTOL-MYERS SQUIBB/60/0.1/21.06.24

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting	07:44pm	BU
Bristol Myers: presents advances in lung cancer	06:28pm	CF
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer	05:39pm	BU
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	02/06	RE

More news

Quotes 5-day view

Date	Price	Change
03/24/03	0.001	0.00%
31/24/31	0.001	0.00%
30/24/30	0.001	0.00%
29/24/29	0.001	0.00%
28/24/28	0.001	0.00%

Delayed Quote Deutsche Boerse AG

Last update June 03, 2024 at 09:25 pm IST

More quotes

Static data

Product type	Warrant Plain-Vanilla
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Société Générale
WKN	SV1KST
ISIN	DE000SV1KST1
Date issued	28/02/2023
Strike	60 $
Maturity	21/06/2024 (18 Days)
Parity	10 : 1
Emission price	1.45 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.4 €
Lowest since issue	0.001 €
Spread	0.019 €
Spread %	95.00%

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Bristol-Myers Squibb Company

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.09 USD

Average target price

53.19 USD

Spread / Average Target

+29.46%

Consensus